Macitentan

Drug Profile

Macitentan

Alternative Names: ACT-064992; Actelion-1; Opsumit; Zependo

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Actelion Pharmaceuticals; Nippon Shinyaku
  • Class Antifibrotics; Antihypertensives; Antineoplastics; Bromobenzenes; Cardiovascular therapies; Pyrimidines; Skin disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action Endothelin A receptor antagonists; Endothelin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension; Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension
  • Phase III Congenital heart defects; Eisenmenger complex
  • Phase II Heart failure
  • Clinical Phase Unknown Portal hypertension
  • Discontinued Glioblastoma; Idiopathic pulmonary fibrosis; Skin ulcer

Most Recent Events

  • 03 Nov 2017 Actelion initiates enrolment in a phase I trial for Healthy volunteers in Germany (NCT03359291)
  • 02 Oct 2017 Phase-III clinical trials in Congenital heart disorders (In children, In adolescents, In adults, In the elderly) in Denmark, Germany, USA (PO) (EudraCT2016-003320-23) (NCT03153137)
  • 21 Aug 2017 Phase-II clinical trials in Heart failure in Sweden, Russia, Romania, Poland, Israel, Germany, France, Denmark, Czech Republic, Bulgaria, USA, United Kingdom (PO), before August 2017 (NCT03153111)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top